Tests Improve Cancer Identification, Help Physicians Develop More Specific
GRAND RAPIDS, Mich., March 3 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced an agreement with San Diego-based AviaraDx to support three new tests that help physicians personalize cancer treatment.
The AviaraDx tests can provide physicians greater understanding of the molecular biology underlying patients' tumors. These test results will help physicians make more informed decisions in managing their oncology patients.
Under the agreement, CMM will educate physicians on the value and clinical utility of the tests, and coordinate quality-controlled sample preparation and shipping. Analysis of the tumor samples will be handled by AviaraDx in California -- a CLIA-certified, CAP-accredited laboratory.
Three tests are available: CancerTYPE ID(SM), H/I(SM) (HOXB13/IL17BR) and MGI(SM) (Molecular Grade Index). The CancerTYPE ID test provides a molecular classification of metastatic cancer, pinpointing the tumor's organ of origin which has important treatment ramifications and can be problematic in a small but significant number of cases. The H/I test measures a two-gene expression signature and is an independent predictor of treatment outcome for breast cancer patients receiving endocrine therapy; the information may be used by physicians to more rationally make the decision about how aggressively to treat, or not treat, against recurrence. Lastly, the MGI test is a five-gene tumor grade signature which discriminates between tumor grades 1 and 3 and is able to reclassify Grade 2 tumors as Grade-1 like and Grade 3-like; many breast tumors are graded as intermediate (Grade 2), which is not clinically useful for the treating oncologist.
"AviaraDx tests are excellent examples of the genomic revolution in
medicine. Test results offer physicians and their patients information they
can use in diagnosin
|SOURCE Center for Molecular Medicine|
Copyright©2008 PR Newswire.
All rights reserved